Startup profile · funding coverage
Forus funding, valuation and investors
AI network that moves specialty prescriptions from doctor order through insurance, assistance, and pharmacy — free for clinics and patients, paid by biopharma.
Keep track of Forus
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C
$150M · September 2026
Latest known valuation
$3B
Series C · September 2026
Total disclosed equity funding
$150M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · New York, NY, USA
Investors in latest funding
Lead: Bain Capital Ventures
Other: Thrive Capital , General Catalyst , Accel , Redpoint Ventures , BoxGroup , Neo
Overview
Forus (formerly Tandem) builds AI agents that navigate prior authorization, financial assistance, and specialty pharmacy fulfillment for each prescription. The New York company says the product is free for doctors and patients and sells network access to biopharma for launch and trial workflows. Founded in 2023; CEO Sahir Jaggi. September 8, 2026 Series C: $150M at $3B led by Bain Capital Ventures with Thrive, General Catalyst, Accel, Redpoint, BoxGroup, Neo and others reinvesting; total disclosed funding exceeds $300M.
Why Forus is interesting
September 8, 2026 $150M Series C at $3B — tripling a ~$1B May mark — underwrites an access layer where the company says more than a third of specialty prescriptions never reach a first dose.
Product & use cases
Per-prescription AI agents that assemble coverage and clinical context, then act across payer portals, documents, phone, and fax to get specialty therapies started.
- Specialty and biologic prior auth / benefits investigation for clinics
- Patient financial assistance and specialty pharmacy coordination
- Biopharma launch, coverage, and trial-recruitment visibility
Key facts
- Series C (Sep 8, 2026): $150M at $3B led by Bain Capital Ventures (company)
- Total disclosed funding >$300M; May 2026 rebrand from Tandem cited >$160M cumulative at ~$1B
- Company claims millions of patients, 85% of U.S. residential ZIP codes, all 50 states
- 9 of top 15 global biopharma companies work with Forus (company)
- Product free for doctors and patients; monetization via biopharma network
Funding history (newest first)
Series C
2026-09 $150M Valuation: $3BInvestors in our directory
Funds linked from Forus's profile — open a fund page for stage focus and related deal articles.
Industries
Related funding articles
Venture Capital Tracker pieces that cover Forus's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.